Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $277 | $387 | $387 | $206 |
| % Growth | -28.3% | 0% | 87.6% | – |
| Cost of Goods Sold | $0 | $1,022 | $1,022 | $373 |
| Gross Profit | $0 | -$635 | -$635 | -$167 |
| % Margin | 0% | -164.3% | -164.3% | -81.1% |
| R&D Expenses | $565 | $619 | $1,289 | $1,337 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $676 | $628 | $497 | $759 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Expenses | $1,241 | $1,247 | $1,787 | $2,096 |
| Operating Income | -$963 | -$1,882 | -$1,882 | -$2,263 |
| % Margin | -347.5% | -486.8% | -486.8% | -1,098.5% |
| Other Income/Exp. Net | $963 | -$186 | -$186 | $33 |
| Pre-Tax Income | $0 | -$2,067 | -$2,067 | -$2,203 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,120 | -$2,067 | -$1,549 | -$2,230 |
| % Margin | -764.5% | -534.8% | -400.8% | -1,082.5% |
| EPS | -18,960 | -1.2 | -1.2 | -5.6 |
| % Growth | -1,579,900% | 0% | 78.6% | – |
| EPS Diluted | -18,960 | -1.2 | -1.2 | -5.6 |
| Weighted Avg Shares Out | 0 | 1,591 | 806 | 392 |
| Weighted Avg Shares Out Dil | 0 | 1,591 | 806 | 1,236 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $11 | $0 |
| Interest Expense | $0 | $186 | $11 | $37 |
| Depreciation & Amortization | $0 | $352 | $352 | $499 |
| EBITDA | -$963 | -$1,530 | -$841 | -$1,667 |
| % Margin | -347.5% | -395.7% | -217.6% | -809.2% |